Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

Nekoohesh, Ladan; Rostami, Shahrbano; Nikbakht, Mohsen; Mohammadi, Saeed; Babakhani, Davood; Ghahremani, Mohammad H.; Chahardouli, Bahram

doi:10.1016/j.clml.2019.09.605

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six studies evaluated the efficacy of generics after switching from original imatinib, [20][21][22][23][24][25] whereas another 7 compared Gleevec with generics in the upfront setting. [26][27][28][29][30][31][32] Additionally, 4 studies reported the combination of both frontline and subsequent uses of generics. 9,[33][34][35] All studies evaluated treatment responses according to the European LeukemiaNet recommendations 36,37 ; however, 1 study 9 assessed patients according to hematologic response level only, and the authors declared results favoring original imatinib in terms of both efficacy and safety (Table 2).…”

Section: Efficacy and Safety Of Generic Imatinibmentioning

confidence: 99%

“…31 Supporting previous findings, in a study consisting of 255 Iranian CML patients receiving frontline generic imatinib, MMR rates at 3, 6, and 12 months of TKI therapy were 15.38%, 25.18%, and 44.1%, respectively, whereas the 7-year probability of OS was reported as 94.3%. 30 In the study by Dou et al, 27 the investigators retrospectively evaluated 442 CML-CP patients receiving branded (n 5 206) or generic (n 5 236) imatinib in the frontline setting. Thirty-one (15%) and 34 (14.4%) patients from the branded and generic imatinib groups experienced treatment failure and switched to 2GTKIs, respectively.…”

Section: Efficacy and Safety Of Generic Imatinibmentioning

confidence: 99%

See 1 more Smart Citation

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Erçalışkan¹,

Erdoğan

Eşkazan³

2021

Blood Advances

View full text Add to dashboard Cite

Since the introduction of imatinib, the management of chronic myeloid leukemia (CML) has changed considerably. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment; however, the high financial burden of TKIs can be problematic for both the patients and health care systems. After the emergence of generics, reimbursement policies of many countries have changed, and generics offered an alternative treatment option for CML patients. There are many papers published on the use of generics in CML patients with conflicting results regarding both efficacy and safety. In this paper, we systematically reviewed the current literature on generic imatinib use in CML, and 36 papers were evaluated. Both in vitro and in vivo studies of generic imatinib showed comparable results with branded imatinib in terms of bioequivalence and bioavailability. In most studies, generics were comparable with the original molecule in terms of efficacy and safety, both in newly diagnosed patients and after switching from Gleevec. Some generic studies showed contradictory findings regarding efficacy and toxicity, and these differences can be attributed to some factors including the use of different generics in different countries. Both in hypothetical models and in real life, introduction of generic imatinib caused significant reduction in health care costs. In conclusion, generics are not inferior to original imatinib in terms of efficacy with an acceptable toxicity profile. Notwithstanding the generally favorable efficacy and safety of generics worldwide to date, we most probably still need more time to draw firmer conclusions on the longer-term outcomes of generics.

show abstract

Section: Efficacy and Safety Of Generic Imatinibmentioning

confidence: 99%

Section: Efficacy and Safety Of Generic Imatinibmentioning

confidence: 99%

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Erçalışkan¹,

Erdoğan

Eşkazan³

2021

Blood Advances

View full text Add to dashboard Cite

show abstract

Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience

Szczepanek

Chukwu

Kamińska

et al. 2022

Leukemia & Lymphoma

View full text Add to dashboard Cite

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Amouei¹,

Daeian²,

Khezrnia³

et al. 2021

IJHOSCR

View full text Add to dashboard Cite

Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survivals. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords in PubMed, Web of science, Scopus, Ovid, ProQuest, Science direct and Google scholar for English studies. We also investigated the aforementioned terms’ correspondence in Magiran, Scientific information database (SID) and Google scholar for Persian articles. Results: 25 studies were selected for final analysis. Reported hematologic responses from adult studies ranged 86-99% and major molecular responses were estimated in 38.84% of our patients within 12 months of treatment. The most frequent reported adverse drug reactions (ADRs) were edema (n=5 studies, 100%) and fatigue and nausea (n=4 studies, 80%); ADR per capita ratio was 1.46. Only one study informed ADRs in pediatrics demonstrating 93% of patients experienced ADRs after receiving imatinib. Most of the Studies (n=4, 67% from 7 studies) considered BCR/ABL point mutation as main reason of imatinib resistance. Drug-binding site and P-loop regions were two common sites for BCR/ABL point mutation. Conclusion: Imatinib as the first line treatment for CML has been associated with proper and durable responses in Iranian adults and children CML patients. Moreover, Imatinib life-threatening adverse effects were reported uncommon. Various responses to modified regimens have been reported in resistant patients; therefore, individualized treatment based on mutation type could be recommended.

show abstract

Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

Cited by 3 publications

References 32 publications

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Contact Info

Product

Resources

About